Instrument Inactif

Autres langues Virbac Other OTC

Actions

VRBCF

FR0000031577

Produits pharmaceutiques

Autres langues

20/08	Cancer vaccines finally garner the spotlight
30/07	Virbac - ohne Ausreden zum Erfolg
30/07	Virbac, sin excusas
29/07	Virbac, het ontbrekende excuus
29/07	Virbac, without the alibi
21/07	Virbac : Impressive execution in Q2; we smell a guidance upgrade in Q3
20/07	Virbac : 2026 second quarter consolidated sales
20/07	Virbac: solid growth of +7.4% at CERS in H1 2026, fueled by double-digit growth of our Supercharge4 platforms
14/07	Where would AI lead Pharma in the long run?
27/05	Governance: regional reorganization to foster proximity
05/05	Virbac : Step into the Daily Life of an Iberian Pig Farm Manager
27/04	Virbac : Public release of Virbac Annual Report at 31 December 2025.
17/04	Virbac : 2026 starts on strong footing
17/04	Swine health: Virbac signs agreement with MACSO
17/04	French and Benelux stocks-Factors to watch April 17
16/04	Virbac SA Reports Consolidated Unaudited Revenue Results for the First Quarter of 2026
16/04	Virbac Q1 revenue EUR 384 mln, maintains 2026 guidance
16/04	Virbac : 2026 first quarter consolidated sales
16/04	Virbac: strong Q1 2026 growth of +7.7% at CERS, driven by double-digit growth of our priority Supercharge4 platforms
13/04	Weekly Earnings Calendar: JPMorgan and Netflix in the US, LVMH and ASML in Europe,
07/04	Virbac : Meet Lucy, a dedicated farm animals vet in Ireland
18/03	Virbac : 2025 full-year results
18/03	French and Benelux stocks-Factors to watch
17/03	Virbac SA Reports Earnings Results for the Full Year Ended December 31, 2025
17/03	Virbac: Public Release of the Year-End Consolidated Accounts at 31 December 2025